Literature DB >> 10493109

Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.

K O Lee1, H Akil, J H Woods, J R Traynor.   

Abstract

This study examines the possibility that oripavine opioid receptor agonists bind equally to both high and low affinity states of the mu-opioid receptor. Studies were performed in C6 cells expressing mu- or delta-opioid receptors; high and low agonist affinity states of the receptors were defined by the absence and presence, respectively of Na+ ions and the GTP analog Gpp(NH)p. At the mu-opioid receptor dihydroetorphine and etorphine were full agonists, buprenorphine had moderate efficacy while diprenorphine was an antagonist. At the delta-opioid receptor, dihydroetorphine, etorphine, and diprenorphine had moderate efficacy while buprenorphine was an antagonist. The binding affinities of the oripavines at the mu-opioid receptor decreased only one to 2-fold in the presence of NaCl and Gpp(NH)p. In contrast, decreases in oripavine affinity at the delta-opioid receptor correlated with delta-opioid receptor efficacy. The ability of oripavine agonists to bind with high affinity to the low agonist affinity state of the nu-opioid receptor may explain the high potencies of these compounds in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493109     DOI: 10.1016/s0014-2999(99)00460-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  46 in total

1.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

3.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

4.  Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.

Authors:  Neil T Burford; Mary J Clark; Tom S Wehrman; Samuel W Gerritz; Martyn Banks; Jonathan O'Connell; John R Traynor; Andrew Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

5.  Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

Authors:  Shefali Srivastava; Emily A Fergason-Cantrell; Roger I Nahas; John R Lever
Journal:  Tetrahedron       Date:  2016-08-04       Impact factor: 2.457

6.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

7.  Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.

Authors:  Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor
Journal:  J Neurochem       Date:  2009-11-30       Impact factor: 5.372

8.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

9.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review.

Authors:  S Deandrea; O Corli; I Moschetti; G Apolone
Journal:  Ther Clin Risk Manag       Date:  2009-09-15       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.